Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Evaxion Biotech, InxMed, AiVita Biomedical, Apexigen, Checkmate Pharma, Nektar therapeutics, Merck & Co., Neon Therapeutics, BioN

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Melanoma pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Metastatic Melanoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Melanoma Pipeline Report: https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years.
• Metastatic Melanoma companies working in the treatment market are TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others, are developing therapies for the Metastatic Melanoma treatment
• Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.
• In October 2024, Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on developing T cell-redirecting cancer immunotherapies, today announced updated Phase 1b clinical data for ACTengine® IMA203 TCR-T targeting PRAME in melanoma patients. The company also provided an update on SUPRAME, the upcoming Phase 3 trial designed to evaluate IMA203 in metastatic melanoma patients.
• In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human study of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy for patients with advanced or metastatic melanoma. This update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included safety data from a 25-week median study follow-up and newly detailed efficacy data.
• In April 2024, Iovance Biotherapeutics revealed that clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma, along with translational data, will be featured at the 2024 ASCO Annual Meeting

Metastatic Melanoma Overview
Metastatic melanoma is an advanced stage of melanoma, a type of skin cancer, where cancer cells have spread from the initial site of the skin or mucous membrane to other parts of the body. This typically involves the lymph nodes, organs, or distant tissues.

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment:
https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:
• TILT 123: TILT Biotherapeutics
• AV-MEL-1: AiVita Biomedical
• IMM-1-104: Immuneering Corporation
• UV1: Ultimovacs ASA
• APX005: MPyxis Oncology
• EVX 01: Evaxion Biotech
• HBI-8000: HUYABIO International, LLC.
• IO102-IO103: IO Biotech
• Fianlimab: Regeneron Pharmaceuticals

Metastatic Melanoma Route of Administration
Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Metastatic Melanoma Molecule Type
Metastatic Melanoma Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Metastatic Melanoma Pipeline Therapeutics Assessment
• Metastatic Melanoma Assessment by Product Type
• Metastatic Melanoma By Stage and Product Type
• Metastatic Melanoma Assessment by Route of Administration
• Metastatic Melanoma By Stage and Route of Administration
• Metastatic Melanoma Assessment by Molecule Type
• Metastatic Melanoma by Stage and Molecule Type

DelveInsight's Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:
Key companies developing therapies for Metastatic Melanoma are - Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, Taizhou Hanzhong biomedical co. LTD, Scancell Ltd, BioMed Valley Discoveries, Inc., Nykode Therapeutics, Sapience Therapeutics, BeiGene, Immunocore, Achilles Therapeutics UK Limited, Vanquish Oncology, Syntrix Biosystems, Inc., TILT Biotherapeutics, PrimeVax Immuno-Oncology Inc., Celldex Therapeutics, Taiga Biotechnologies, Inc., Galectin Therapeutics Inc, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., Miltenyi Biomedicine GmbH, CytomX Therapeutics, Inc., Seagen Inc., Immutep, Regeneron pharmaceuticals, Adaptimmune, IDEAYA Biosciences, PokeAcell, Ultimovacs ASA, Verastem, Inc., PACT Pharma, Actuate Therapeutics, Inc., and others.

Metastatic Melanoma Pipeline Analysis:
The Metastatic Melanoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
• Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Melanoma Pipeline Market Drivers
• Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

Metastatic Melanoma Pipeline Market Barriers
• However, lack Of Cost-Effective Treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

Scope of Metastatic Melanoma Pipeline Drug Insight
• Coverage: Global
• Key Metastatic Melanoma Companies: TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, IO Biotech, Checkmate Pharmaceuticals, Evaxion Biosciences, Apexigen, Inc., Biocad, Zucero Therapeutics, Karyopharm Therapeutics, Bristol-Myers Squibb, Viralytics, Nykode Therapeutics, and others
• Key Metastatic Melanoma Therapies: TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
• Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies
• Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers

Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Metastatic Melanoma Report Introduction
2. Metastatic Melanoma Executive Summary
3. Metastatic Melanoma Overview
4. Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment
5. Metastatic Melanoma Pipeline Therapeutics
6. Metastatic Melanoma Late Stage Products (Phase II/III)
7. Metastatic Melanoma Mid Stage Products (Phase II)
8. Metastatic Melanoma Early Stage Products (Phase I)
9. Metastatic Melanoma Preclinical Stage Products
10. Metastatic Melanoma Therapeutics Assessment
11. Metastatic Melanoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Metastatic Melanoma Key Companies
14. Metastatic Melanoma Key Products
15. Metastatic Melanoma Unmet Needs
16 . Metastatic Melanoma Market Drivers and Barriers
17. Metastatic Melanoma Future Perspectives and Conclusion
18. Metastatic Melanoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Metastatic Melanoma Market https://www.delveinsight.com/report-store/metastatic-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).

Latest Reports:
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.